Factors Associated to Success of Hepatitis C Therapy

UPECLIN HC FM Botucatu Unesp

Status: Completed

Conditions: Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

Treatments: Drug: pegylated-interferon, conventional-interferon, ribavirin

Study type: Observational

Funder types: Other

Identifiers

NCT00514111

upeclin/HC/FMB-Unesp-16

Details and patient eligibility

About

The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.

Full description

Chronic hepatitis C virus(HVC) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. In Brazil, it is estimated three million estimated cases to 52 thousand reports. The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.

Enrollment: 100 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HVC patients that received specific treatment with pegylated-interferon or conventional-interferon, and ribavirin

Exclusion criteria

• No HVC infection or treatment

Trial design

100 participants in 1 patient group

HVC Patients

Description:

HVC patients attended in SAE e HD.

Treatment:

Drug: pegylated-interferon, conventional-interferon, ribavirin